Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734 von Morrison-Smiths, Chevaun D., Knox, Tatiana M., Filic, Ivona, Soroko, Kara M., Eschle, Benjamin K., Wilkens, Margaret K., Gokhale, Prafulla C., Giles, Francis, Griffin, Andrew, Browns, Bill, Shapiro, Geoffrey, Zucconi, Beth E., Cole, Philip A., Lemieuxs, Madeleine E., French, Christopher A.

Volltext

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma von Iorgulescu, J. Bryan, Gokhale, Prafulla C., Speranza, Maria C., Eschle, Benjamin K., Poitras, Michael J., Wilkens, Margaret K., Soroko, Kara M., Chhoeu, Chhayheng, Knott, Aine, Gao, Yan, Lim-Fat, Mary Jane, Baker, Gregory J., Bonal, Dennis M., Nguyen, Quang-De, Grant, Gareth R. L., Ligon, Keith L., Sorger, Peter K., Chiocca, E. Antonio, Anderson, Ana C., Kirschmeier, Paul T., Sharpe, Arlene H., Freeman, Gordon J., Reardon, David A.

Volltext

Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC von Gero, Thomas W., Heppner, David E., Beyett, Tyler S., To, Ciric, Azevedo, Seth C., Jang, Jaebong, Bunnell, Thomas, Feru, Frederic, Li, Zhengnian, Shin, Bo Hee, Soroko, Kara M., Gokhale, Prafulla C., Gray, Nathanael S., Jänne, Pasi A., Eck, Michael J., Scott, David A.

Volltext

ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer von Kohler, Jens, Zhao, Yutong, Li, Jiaqi, Gokhale, Prafulla C., Tiv, Hong L., Knott, Aine R., Wilkens, Margaret K., Soroko, Kara M., Lin, Mika, Ambrogio, Chiara, Musteanu, Monica, Ogino, Atsuko, Choi, Jihyun, Bahcall, Magda, Bertram, Arrien A., Chambers, Emily S., Paweletz, Cloud P., Bhagwat, Shripad, Manro, Jason R., Tiu, Ramon, Janne, Pasi A.

Volltext

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer von To, Ciric, Beyett, Tyler S, Jang, Jaebong, Feng, William W, Bahcall, Magda, Haikala, Heidi M, Shin, Bo H, Heppner, David E, Rana, Jaimin K, Leeper, Brittaney A, Soroko, Kara M, Poitras, Michael J, Gokhale, Prafulla C, Kobayashi, Yoshihisa, Wahid, Kamal, Kurppa, Kari J, Gero, Thomas W, Cameron, Michael D, Ogino, Atsuko, Mushajiang, Mierzhati, Xu, Chunxiao, Zhang, Yanxi, Scott, David A, Eck, Michael J, Gray, Nathanael S, Jänne, Pasi A

Volltext

Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model von Iorgulescu, J Bryan, Ruthen, Neil, Ahn, Ryuhjin, Panagioti, Eleni, Gokhale, Prafulla C, Neagu, Martha, Speranza, Maria C, Eschle, Benjamin K, Soroko, Kara M, Piranlioglu, Raziye, Datta, Meenal, Krishnan, Shanmugarajan, Yates, Kathleen B, Baker, Gregory J, Jain, Rakesh K, Suvà, Mario L, Neuberg, Donna, White, Forest M, Chiocca, E Antonio, Freeman, Gordon J, Sharpe, Arlene H, Wu, Catherine J, Reardon, David A

Volltext

Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma von Ananthapadmanabhan, Varsha, Frost, Thomas C, Soroko, Kara M, Knott, Aine, Magliozzi, Brianna J, Gokhale, Prafulla C, Tirunagaru, Vijaya G, Doebele, Robert C, DeCaprio, James A

Volltext

Abstract P203: Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines von Ananthapadmanabhan, Varsha, Knott, Aine, Soroko, Kara M., Gokhale, Prafulla C., Tirunagaru, Vijaya, Doebele, Robert, DeCaprio, James A.

Volltext

Milademetan is a highly potent MDM2 inhibitor in TP53 wild-type (p53 WT) models of Merkel cell carcinoma (MCC) von Ananthapadmanabhan, Varsha, Frost, Thomas C., Soroko, Kara M., Knott, Aine, Magliozzi, Brianna, Gokhale, Prafulla C., Tirunagaru, Vijaya, Doebele, Robert C., DeCaprio, James A.

Volltext

Establishment of the Bcwm.2 Cell Line As a BTK-Inhibitor Resistant, BCL2 Inhibitor Sensitive in Vitro and In Vivo Study Model for Waldenström's Macroglobulinemia von Liu, Shirong, Liu, Xia, Soroko, Kara M, Canning, Alexa G, Kofides, Amanda, Yusuf, Choudhury Fabliha Binte, Penailillo, Johany, Tsakmaklis, Nickolas, Patterson, Christopher J, Carrasco, Ruben D., Hunter, Zachary R, Gokhale, Prafulla C., Sarosiek, Shayna R, Castillo, Jorge J., Treon, Steven P

Volltext

IMMU-09. CONCURRENT DEXAMETHASONE LIMITS THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA von Iorgulescu, Bryan, Gokhale, Prafulla, Speranza, Maria, Eschle, Benjamin, Poitras, Michael, Wilkens, Margaret, Soroko, Kara, Chhoeu, Chhayheng, Knott, Aine, Gao, Yang, Lim-Fat, Mary Jane, Baker, Gregory, Bonal, Dennis, Nguyen, Quang-De, Grant, Gareth, Ligon, Keith, Sorger, Peter, Chiocca, E Antonio, Anderson, Ana, Kirschmeier, Paul, Sharpe, Arlene, Freeman, Gordon, Reardon, David

Volltext

Abstract 2990: Antigen presentation deficiency and mesenchymal differentiation underlie resistance to immunotherapy in the murine syngeneic CT2A tumor model von Iorgulescu, Bryan, Ruthen, Neil, Ahn, Ryuhjin, Panagioti, Eleni, Gokhale, Prafulla, Neagu, Martha, Speranza, Maria, Eschle, Benjamin, Soroko, Kara, Piranlioglu, Raziye, Datta, Meenal, Krishnan, Shanmugarajan, Yates, Kathleen, Baker, Gregory, Jain, Rakesh, Suva, Mario, Neuberg, Donna, White, Forest, Chiocca, E., Freeman, Gordon, Sharpe, Arlene, Wu, Catherine, Reardon, David

Volltext

Allosteric inhibition of drug resistant forms of EGFR L858R mutant NSCLC von To, Ciric, Beyett, Tyler S., Jang, Jaebong, Feng, William W., Bahcall, Magda, Haikala, Heidi M., Shin, Bo H., Heppner, David E., Rana, Jaimin K., Leeper, Brittaney A., Soroko, Kara M., Poitras, Michael J., Gokhale, Prafulla C., Kobayashi, Yoshihisa, Wahid, Kamal, Kurppa, Kari J., Gero, Thomas W., Cameron, Michael D., Ogino, Atsuko, Mushajiang, Mierzhati, Xu, Chunxiao, Zhang, Yanxi, Scott, David A., Eck, Michael J., Gray, Nathanael S., Jänne, Pasi A.

Volltext